GSK Bio
NEWS
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Following the announcement that Slaoui was tapped to helm Operation Warp Speed, Jim Greenwood, president and CEO of BIO, hailed that decision.
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.
Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
JOBS
IN THE PRESS